High-dose interleukin 2-induced myocarditis: Can myocardial damage reversibility be assessed by cardiac MRI?

Journal of Immunotherapy

Volumn 37, Issue 5, 2014, Pages 304-308

  Chow, Shien ^a   Cove Smith, Laura ^b   Schmitt, Matthias ^c   Hawkins, Robert ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

adoptive cell therapy; high dose interleukin 2; IL2; immunotherapy; metastatic renal cell carcinoma; myocarditis

Indexed keywords

ANTICOAGULANT AGENT; DIURETIC AGENT; GADOLINIUM; INTERLEUKIN 2; SUNITINIB; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANT THERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CEREBROVASCULAR DISEASE; CONTRAST ENHANCEMENT; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; DYSPNEA; FACE MALFORMATION; FEMALE; HEART ATRIUM THROMBOSIS; HEART EJECTION FRACTION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LIFESTYLE; LUNG EDEMA; LUNG METASTASIS; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; PRIORITY JOURNAL; REPEAT PROCEDURE; SECOND CANCER; SITTING; SLURRED SPEECH; SUMMER; T WAVE INVERSION; TAKOTSUBO CARDIOMYOPATHY; THORAX PAIN; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT RESPONSE; ADVERSE EFFECTS; BLOOD; CARCINOMA; DOSE CALCULATION; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; REMISSION; TREATMENT WITHDRAWAL;

ACUTE CORONARY SYNDROME; ADULT; CARCINOMA; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDITIS; NEOPLASM METASTASIS; REMISSION INDUCTION; TROPONIN T; WITHHOLDING TREATMENT;

EID: 84900526697     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000036     Document Type: Article

References (15)

1. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57.
2. Atkins MB, Kunkel L. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long term survival update. Cancer J Sci Am. 2000;6(suppl 1):S11-S14.
3. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21: 3127-3132. (Pubitemid 46606294)
4. Clement JM, McDermott DF. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009;7:e7-e9.
5. Shablak A, Hawkins RE, Sikand K, et al. High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother. 2011;34:107-112.
6. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother. 2001;24: 287-293. (Pubitemid 32825860)
7. Ingkanisorn WP, Paterson DI, Aral AE, et al. Cardiac magnetic resonance appearance of myocarditis caused by high dose IL-2: similarities to community-acquired myocarditis. J Cardiovasc Magn Reson. 2006;8:353-360.
8. Kragel AH, Travis WD, Steis RG, et al. Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer. 1990;66:1513-1516. (Pubitemid 20355418)
9. Thavendiranathan P, Verhaert D, Raman SV, et al. Fulminant myocarditis owing to high-dose interleukin-2 therapy for metastatic melanoma. Br J Radiol. 2011;84:e99-e102.
10. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83:797-805. (Pubitemid 28387707)
11. Du Bois JS, Udelson JE, Atkins MB. Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy. J Immunother Emphasis Tumor Immunol. 1995;18:119-123.
12. Samlowski WE, Ward JH, Craven CM, et al. Severe myocarditis following high-dose interleukin-2 administration. Arch Pathol Lab Med. 1989;113:838-841. (Pubitemid 19206382)
13. Monney PA, Sekhri N, Mohiddin SA. Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis. Heart. 2011;97:1312-1318.
14. Mewton N, Liu CY, Lima JA, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891-903.
15. Hunold P, Schlosser T, Barkhausen J. Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease. Am J Roentgenol. 2005;184:1420-1426. (Pubitemid 43821809)